Skip to main content

Loading market data...

AMGN

Amgen Inc.

NASDAQ • United states

$434.90

+$9.96

(+2.34%)

Source: Yahoo Finance · Quote time Oct 20, 2026 13:47 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Amgen Inc. (AMGN)

Unavailable

Quotes may be delayed

$235.12B

Market Cap

174,381

Volume

26.9

P/E Ratio

2.27%

Div Yield

Amgen Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

4 Aug 2026

Amgen Inc. filed Form 10-Q

Amgen Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

4 Aug 2026

Amgen Inc. reported Operating or financial results

Amgen Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

31 Jul 2026

Amgen Inc. reported A material cybersecurity incident

Amgen Inc. filed an 8-K covering a material cybersecurity incident.

20 May 2026

Amgen Inc. reported Shareholder voting results

Amgen Inc. filed an 8-K covering shareholder voting results.

19 May 2026

Amgen Inc. reported A director or senior management change or compensation event

Amgen Inc. filed an 8-K covering a director or senior management change or compensation event.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$13.99B

Total assets (USD)$95.64B

Shareholders' equity (USD)$11.69B

Long-term debt (USD)$51.86B

Debt due within a year (USD)$5.45B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$10.05B	$3.51B	$2.38B	$4.37	10-Q · 5 Aug 2026
Q1 2026	$8.62B	$2.67B	$1.82B	$3.34	10-Q · 1 May 2026
Q4 2025	$9.87B	$2.72B	$1.33B	Unavailable	10-K · 13 Feb 2026
Q3 2025	$9.56B	$2.53B	$3.22B	$5.93	10-Q · 5 Nov 2025
Q2 2025	$9.18B	$2.66B	$1.43B	$2.65	10-Q · 6 Aug 2025
Q1 2025	$8.15B	$1.18B	$1.73B	$3.20	10-Q · 2 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $403.33

-7.3% upside potential

📈

Strong Buy

Unavailable

👍

Buy

9

⏸️

Hold

14

📉

Sell

2

25 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 13:47 UTC Targets range 230.00–500.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

13

Aug 2026

Khosla Rachna

SVP, Business Development

Option exercise

$162.60 per share

1,252 shares

13

Aug 2026

Khosla Rachna

SVP, Business Development

Open-market sale

$416.43 per share

1,252 shares

11

Aug 2026

Khosla Rachna

SVP, Business Development

Open-market sale

$412.57 per share

2,000 shares

7

Aug 2026

Busch Matthew C.

VP, Finance & CAO

Grant or award

Unavailable per share

730 shares

7

Aug 2026

ISHRAK OMAR

Director

Grant or award

Unavailable per share

85 shares

7

Aug 2026

HOLLEY CHARLES M

Director

Grant or award

Unavailable per share

103 shares

7

Aug 2026

Drake Michael V

Director

Grant or award

Unavailable per share

64 shares

6

Aug 2026

Miller Derek

SVP, Human Resources

Option exercise

$169.56 per share

3,890 shares

6

Aug 2026

Miller Derek

SVP, Human Resources

Open-market sale

$402.54 per share

3,890 shares

6

Aug 2026

Grygiel Nancy A.

SVP & CCO

Option exercise

$177.41 per share

2,970 shares

Top Shareholders

Vanguard Group Inc

54,838,826 shares

1.786% change

12/31/2025

Blackrock, Inc.

49,362,016 shares

4.802% change

6/30/2026

Vanguard Capital Management Llc

35,250,101 shares

0.674% change

6/30/2026

State Street Corp

30,560,537 shares

0.039% change

6/30/2026

Capital World Investors

29,075,329 shares

-0.727% change

6/30/2026

Invesco Ltd.

16,320,446 shares

2.738% change

6/30/2026

Geode Capital Management, Llc

15,696,068 shares

1.721% change

6/30/2026

Charles Schwab Investment Management Inc

15,034,038 shares

17.698% change

6/30/2026

Vanguard Portfolio Management Llc

14,853,366 shares

1.588% change

6/30/2026

Morgan Stanley

13,653,692 shares

-13.781% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 13:47 UTC· 1 day ago

Research coverage and investment tools

Amgen Inc. (AMGN) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)). Its last price was US$434.90 on 20 Oct 2026. That is 92% of the way from its 52-week low of US$288.00 to its 52-week high of US$447.03. It paid US$9.94 a share in dividends over the last 12 months, a dividend yield of 2.27%. The latest ex-dividend date on file is 21 Aug 2026. Its market capitalisation was US$235.12 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$10.05B	$3.51B	$2.38B	$4.37	—	35.0%	$3.49B	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2026	$8.62B	$2.67B	$1.82B	$3.34	—	30.9%	$1.48B	10-Q · 1 May 2026 (opens in a new tab)
Q4 2025	$9.87B	$2.72B	$1.33B	Unavailable	—	27.6%	$961.00M	10-K · 13 Feb 2026 (opens in a new tab)
Q3 2025	$9.56B	$2.53B	$3.22B	$5.93	—	26.4%	$4.25B	10-Q · 5 Nov 2025 (opens in a new tab)
Q2 2025	$9.18B	$2.66B	$1.43B	$2.65	—	28.9%	$1.91B	10-Q · 6 Aug 2025 (opens in a new tab)
Q1 2025	$8.15B	$1.18B	$1.73B	$3.20	—	14.5%	$980.00M	10-Q · 2 May 2025 (opens in a new tab)

Cash and equivalents: $13.99B
Total assets: $95.64B
Shareholders' equity: $11.69B
Long-term debt: $51.86B
Debt due within a year: $5.45B

10-Q · 4 Aug 2026

Amgen Inc. filed Form 10-Q (opens in a new tab)

Amgen Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 4 Aug 2026

Amgen Inc. reported Operating or financial results (opens in a new tab)

Amgen Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
8-K · 31 Jul 2026 · Cybersecurity incident

Amgen Inc. reported A material cybersecurity incident (opens in a new tab)

Amgen Inc. filed an 8-K covering a material cybersecurity incident.
8-K · 20 May 2026

Amgen Inc. reported Shareholder voting results (opens in a new tab)

Amgen Inc. filed an 8-K covering shareholder voting results.
8-K · 19 May 2026 · Management change

Amgen Inc. reported A director or senior management change or compensation event (opens in a new tab)

Amgen Inc. filed an 8-K covering a director or senior management change or compensation event.

Insider	Date	Transaction	Shares	Average price	Filing
Khosla Rachna SVP, Business Development	13 Aug 2026	Option exercise (M)	+1,252	$162.60	Form 4 (opens in a new tab)
Khosla Rachna SVP, Business Development	13 Aug 2026	Open-market sale (S)	−1,252	$416.43	Form 4 (opens in a new tab)
Khosla Rachna SVP, Business Development	11 Aug 2026	Open-market sale (S)	−2,000	$412.57	Form 4 (opens in a new tab)
Busch Matthew C. VP, Finance & CAO	7 Aug 2026	Grant or award (A)	+730	—	Form 4 (opens in a new tab)
ISHRAK OMAR Director	7 Aug 2026	Grant or award (A)	+85	—	Form 4 (opens in a new tab)
HOLLEY CHARLES M Director	7 Aug 2026	Grant or award (A)	+103	—	Form 4 (opens in a new tab)
Drake Michael V Director	7 Aug 2026	Grant or award (A)	+64	—	Form 4 (opens in a new tab)
Miller Derek SVP, Human Resources	6 Aug 2026	Option exercise (M)	+3,890	$169.56	Form 4 (opens in a new tab)
Miller Derek SVP, Human Resources	6 Aug 2026	Open-market sale (S)	−3,890	$402.54	Form 4 (opens in a new tab)
Grygiel Nancy A. SVP & CCO	6 Aug 2026	Option exercise (M)	+2,970	$177.41	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	54,838,826	1.786%
Blackrock, Inc.	6/30/2026	49,362,016	4.802%
Vanguard Capital Management Llc	6/30/2026	35,250,101	0.674%
State Street Corp	6/30/2026	30,560,537	0.039%
Capital World Investors	6/30/2026	29,075,329	-0.727%
Invesco Ltd.	6/30/2026	16,320,446	2.738%
Geode Capital Management, Llc	6/30/2026	15,696,068	1.721%
Charles Schwab Investment Management Inc	6/30/2026	15,034,038	17.698%
Vanguard Portfolio Management Llc	6/30/2026	14,853,366	1.588%
Morgan Stanley	6/30/2026	13,653,692	-13.781%

Previous close: 424.94 USD
Day range: 425.11 – 434.99 USD
52-week range: 288.00 – 447.03 USD
Volume: 174,381
Market cap: $235.12B
Average volume: 2,745,647
P/E ratio: 26.9
EPS (FY 2025, diluted): 14.23 USD
Dividends (last 12 months): 9.94 USD
Dividend yield: 2.27%
Ex-dividend date: 21 Aug 2026
Shares outstanding: 540.63M
Beta (5Y monthly): 0.44

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 13:47 UTC· 1 day ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:19 UTC· 54 minutes ago

Dividends: Yahoo Finance dividend history (opens in a new tab) Observed 22 Oct 2026, 06:19 UTC· 54 minutes ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding. What dividend yield leaves out: dividend yield vs total return

This research is not available for AMGN yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.